ClinicalTrials.gg
CompletedNCT02291861AIM-TDUpdated Jun 23, 2026Results posted

Addressing Involuntary Movements in Tardive Dyskinesia

A Phase 3 interventional study of SD-809 and Placebo in Tardive Dyskinesia, sponsored by Auspex Pharmaceuticals, Inc.. Completed at 106 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Auspex Pharmaceuticals, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
298
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Tardive Dyskinesia with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Tardive Dyskinesia · United States.

Enrollment
3rd of 27
298 · median 89
Started
2014
with 4 others
Phase 3
6 of 31
none open now
Registered
14th of 31
by date
Lead sponsor
3 of 31
Auspex Pharmaceuticals, Inc.

Among the 31 studies in Tardive Dyskinesia with a site in United States, this one is the 3rd largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2014, is one of 6 in phase 3, and was the 14th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

6 of the 31 studies in Tardive Dyskinesia with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Tardive Dyskinesia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.

03

Conditions studied

  • Tardive Dyskinesia

Keywords

  • Dyskinesias
  • Movement Disorders
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Neurologic Manifestations
  • Signs and Symptoms
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of using a dopamine receptor antagonist for at least 3 months
  • Clinical diagnosis of tardive dyskinesia and has had symptoms for at least 3 months prior to screening
  • Subjects with underlying psychiatric diagnosis are stable and have no change in psychoactive medications
  • Have a mental health provider and does not anticipate any changes to treatment regimen in the next 3 months
  • History of being compliant with prescribed medications
  • Able to swallow study drug whole
  • Be in good general health and is expected to attend all study visits and complete study assessments
  • Female subjects must not be pregnant and must agree to an acceptable method of throughout the study

Exclusion criteria

Exclusion Criteria:

  • Currently receiving medication for the treatment of tardive dyskinesia
  • Have a neurological condition other than tardive dyskinesia that may interfere with assessing the severity of dyskinesias
  • Have a serious untreated or undertreated psychiatric illness
  • Have recent history or presence of violent behavior
  • Have unstable or serious medical illness
  • Have evidence of hepatic impairment
  • Have evidence of renal impairment
  • Have known allergy to any component of SD-809 or tetrabenazine
  • Has participated in an drug or device trial and received study drug or device within 30 days
  • Have acknowledged use of illicit drugs
  • Have a history of alcohol or substance abuse in the previous 12 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
298 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo tablets taken twice daily for 12 weeks.

    Drug: Placebo

  • Experimental
    SD-809 12 mg/day

    SD-809 tablets 6 mg taken twice a day (BID) for 12 weeks.

    Drug: SD-809

  • Experimental
    SD-809 24 mg/day

    SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 12 mg BID. The total daily dose of 24 mg was maintained for an additional 8 weeks.

    Drug: SD-809

  • Experimental
    SD-809 36 mg/day

    SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 18 mg BID. The total daily dose of 36 mg was maintained for an additional 8 weeks.

    Drug: SD-809

Interventions

  • DrugSD-809

    SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.

    Also known as: deutetrabenzine, Austedo

  • DrugPlacebo

    Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.

06

What researchers measure

Primary outcomes

  1. Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM)

    AIMS is an assessment tool used to detect and follow the severity of tardive dyskinesia (TD) over time. AIMS is composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement. MMRM with treatment group, visit, treatment group-by-visit interaction, and baseline use of dopamine receptor antagonist (DRAs) as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.

    Time frame: Day 0 (Baseline), Weeks 2, 4, 8 and 12

Secondary outcomes

  1. Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC)

    The CGIC is a single-item questionnaire that asks the investigator to assess a patient's TD symptoms at specific visits after initiating therapy. The CGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures. The success 95% confidence interval (CI) was calculated with the Wilson (score) confidence limits.

    Time frame: Week 12

  2. Change in the Modified Craniocervical Dystonia Questionnaire (mCDQ-24) Total Score From Baseline to Week 12

    The CDQ-24 is a disease-specific quality of life questionnaire developed for use in patients with craniocervical dystonia, including both cervical dystonia (CD) and blepharospasm (BPS). The CDQ 24 was modified such that the questions focus more directly on the impact of TD (as opposed to CD/BPS) on quality of life. The following domains are evaluated in the mCDQ-24: stigma, emotional well-being, pain, activities of daily living, and social/family life. Each of the 24 questions were rated by patients on a scale of 0=no impairment to 4=severest impairment for a total scale of 0 - 96. Negative change from baseline scores indicate improvement. For patients with missing data at week 12, the baseline or last available value was used as the week 12 value.

    Time frame: Day 0 (Baseline), Week 12

  3. Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC)

    The PGIC is a single-item questionnaire that asks the patient to assess their TD symptoms at specific visits after initiating therapy. The PGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures. The success 95% CI was calculated with the Wilson (score) confidence limits.

    Time frame: Week 12

  4. Percentage of Participants Who Had a 50% or Greater Reduction in Total Motor Abnormal Involuntary Movement Scale (AIMS) From Baseline to Week 12

    Responders who had a 50% or greater improvement in total motor modified AIMS at Week 12 as compared to baseline were reported as a percentage of participants with an outcome at Week 12. The responder 95% CI is calculated with the Wilson (score) confidence limits. AIMS is an assessment tool used to detect and follow the severity of TD over time. AIMS is composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement.

    Time frame: Day 0 (Baseline), Week 12

  5. Percent Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model for Repeated Measures (MMRM)

    AIMS is an assessment tool used to detect and follow the severity of TD over time. AIMS is composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement. MMRM with treatment group, visit, treatment group-by-visit interaction, and baseline use of DRAs as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.

    Time frame: Day 0 (Baseline), Weeks 2, 4, 8 and 12

  6. Cumulative Percentage of Responders Based on Change in in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Recorded in Incremental Steps of 10 Percentage Points

    AIMS is an assessment tool used to detect and follow the severity of TD over time, composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement. Participants with missing data are classified as non-responders. The responder 95% CI is calculated with the Wilson (score) confidence limits. If any of the expected cell counts are \< 5, exact Clopper Pearson limits are presented. Data report the percentage of participants who responded to the percentage improvement indicated in each row.

    Time frame: Day 0 (Baseline), Week 12

  7. Participants With Adverse Events During the Overall Treatment Period

    An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator and includes possibly, probably and definitely related categories. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

    Time frame: Day 1 to Week 12

07

Results

Posted Apr 11, 2018

Participant flow

This study was performed at 75 study centers (38 in the US, 19 in Poland, 7 in Hungary, 6 in the Czech Republic, 3 in Slovakia, and 2 in Germany) by 75 investigators; 298 patients were enrolled.

Participant flow — Overall Study
MilestonePlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/Day
Started74757475
Safety population72747374
Modified intent to treat pop (mitt)58604955
Completed67676565
Not completed78910
Withdrew: Adverse event2412
Withdrew: Death0011
Withdrew: Protocol violation1001
Withdrew: Withdrawal by subject1214
Withdrew: Noncompliance1121
Withdrew: Lost to follow-up2140
Withdrew: Other0001

Outcome measures

PrimaryChange in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM)

AIMS is an assessment tool used to detect and follow the severity of tardive dyskinesia (TD) over time. AIMS is composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement. MMRM with treatment group, visit, treatment group-by-visit interaction, and baseline use of dopamine receptor antagonist (DRAs) as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.

Time frame:
Day 0 (Baseline), Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · units on a scale
Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM)
units on a scalePlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/Day
Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM)-1.4 ± 0.41-2.1 ± 0.42-3.2 ± 0.45-3.3 ± 0.42
Statistical analysis
  • Placebo vs SD-809 36 mg/Day · mixed model for repeated measures · p = 0.001 (Treatment group, visit, treatment group-by-visit interaction, and baseline use of DRAs as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.) · Lsm difference: -1.9 · 95% CI -3.09 to -0.79SD-809 - placebo
  • Placebo vs SD-809 24 mg/Day · mixed model for repeated measures · p = 0.003 (Treatment group, visit, treatment group-by-visit interaction, and baseline use of DRAs as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.) · Lsm difference: -1.8 · 95% CI -3.00 to -0.63SD-809 - placebo
  • Placebo vs SD-809 12 mg/Day · mixed model for repeated measures · p = 0.217 (Treatment group, visit, treatment group-by-visit interaction, and baseline use of DRAs as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.) · Lsm difference: -0.7 · 95% CI -1.84 to 0.42SD-809 - placebo
SecondaryPercentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC)

The CGIC is a single-item questionnaire that asks the investigator to assess a patient's TD symptoms at specific visits after initiating therapy. The CGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures. The success 95% confidence interval (CI) was calculated with the Wilson (score) confidence limits.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC)
percentage of participantsPlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/Day
Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC)26 (16.3 to 38.4)28 (18.5 to 40.8)49 (35.6 to 62.5)44 (31.4 to 56.7)
Statistical analysis
  • Placebo vs SD-809 36 mg/Day · Cochran-Mantel-Haenszel · p = 0.059 · Odds ratio (or): 2.11 · 95% CI 0.960 to 4.645SD-809/placebo The odds ratio was the Mantel-Haenszel estimate of the common odds ratio.
  • Placebo vs SD-809 24 mg/Day · Cochran-Mantel-Haenszel · p = 0.014 · Odds ratio (or): 2.71 · 95% CI 1.211 to 6.052SD-809/placebo The odds ratio was the Mantel-Haenszel estimate of the common odds ratio.
  • Placebo vs SD-809 12 mg/Day · Cochran-Mantel-Haenszel · p = 0.734 · Odds ratio (or): 1.15 · 95% CI 0.509 to 2.610SD-809/placebo The odds ratio was the Mantel-Haenszel estimate of the common odds ratio.
SecondaryChange in the Modified Craniocervical Dystonia Questionnaire (mCDQ-24) Total Score From Baseline to Week 12

The CDQ-24 is a disease-specific quality of life questionnaire developed for use in patients with craniocervical dystonia, including both cervical dystonia (CD) and blepharospasm (BPS). The CDQ 24 was modified such that the questions focus more directly on the impact of TD (as opposed to CD/BPS) on quality of life. The following domains are evaluated in the mCDQ-24: stigma, emotional well-being, pain, activities of daily living, and social/family life. Each of the 24 questions were rated by patients on a scale of 0=no impairment to 4=severest impairment for a total scale of 0 - 96. Negative change from baseline scores indicate improvement. For patients with missing data at week 12, the baseline or last available value was used as the week 12 value.

Time frame:
Day 0 (Baseline), Week 12
Reported as:
Least squares mean · units on a scale
Change in the Modified Craniocervical Dystonia Questionnaire (mCDQ-24) Total Score From Baseline to Week 12
units on a scalePlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/Day
Change in the Modified Craniocervical Dystonia Questionnaire (mCDQ-24) Total Score From Baseline to Week 12-7.1 ± 2.06-5.8 ± 2.03-10.2 ± 2.21-10.7 ± 2.04
Statistical analysis
  • Placebo vs SD-809 36 mg/Day · ANCOVA · p = 0.207 (5% level of significance (2-sided)) · Lsm difference: -3.6 · 95% CI -9.18 to 2.00SD-809 - placebo
  • Placebo vs SD-809 24 mg/Day · ANCOVA · p = 0.281 (5% level of significance (2-sided)) · Lsm difference: -3.1 · 95% CI -8.86 to 2.59SD-809 - placebo
  • Placebo vs SD-809 12 mg/Day · ANCOVA · p = 0.627 (5% level of significance (2-sided)) · Lsm difference: 1.3 · 95% CI -4.10 to 6.79SD-809 - placebo
SecondaryPercentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC)

The PGIC is a single-item questionnaire that asks the patient to assess their TD symptoms at specific visits after initiating therapy. The PGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures. The success 95% CI was calculated with the Wilson (score) confidence limits.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC)
percentage of participantsPlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/Day
Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC)31 (20.6 to 43.8)23 (14.4 to 35.4)45 (31.9 to 58.7)40 (28.1 to 53.2)
Statistical analysis
  • Placebo vs SD-809 36 mg/Day · Cochran-Mantel-Haenszel · p = 0.296 (5% level of significance (2-sided)) · Odds ratio (or): 1.51 · 95% CI 0.694 to 3.285SD-809/placebo The odds ratio was the Mantel-Haenszel estimate of the common odds ratio.
  • Placebo vs SD-809 24 mg/Day · Cochran-Mantel-Haenszel · p = 0.134 (5% level of significance (2-sided)) · Odds ratio (or): 1.82 · 95% CI 0.826 to 3.994SD-809/placebo The odds ratio was the Mantel-Haenszel estimate of the common odds ratio.
  • Placebo vs SD-809 12 mg/Day · Cochran-Mantel-Haenszel · p = 0.372 (5% level of significance (2-sided)) · Odds ratio (or): 0.69 · 95% CI 0.302 to 1.563SD-809/placebo The odds ratio was the Mantel-Haenszel estimate of the common odds ratio.
SecondaryPercentage of Participants Who Had a 50% or Greater Reduction in Total Motor Abnormal Involuntary Movement Scale (AIMS) From Baseline to Week 12

Responders who had a 50% or greater improvement in total motor modified AIMS at Week 12 as compared to baseline were reported as a percentage of participants with an outcome at Week 12. The responder 95% CI is calculated with the Wilson (score) confidence limits. AIMS is an assessment tool used to detect and follow the severity of TD over time. AIMS is composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement.

Time frame:
Day 0 (Baseline), Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Had a 50% or Greater Reduction in Total Motor Abnormal Involuntary Movement Scale (AIMS) From Baseline to Week 12
percentage of participantsPlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/Day
Percentage of Participants Who Had a 50% or Greater Reduction in Total Motor Abnormal Involuntary Movement Scale (AIMS) From Baseline to Week 1212 (6.0 to 22.9)13 (6.9 to 24.2)35 (22.9 to 48.7)33 (21.8 to 45.9)
Statistical analysis
  • Placebo vs SD-809 36 mg/Day · Cochran-Mantel-Haenszel · p = 0.007 (5% level of significance (2-sided)) · Odds ratio (or): 3.80 · 95% CI 1.395 to 10.359SD-809/placebo The odds ratio was the Mantel-Haenszel estimate of the common odds ratio.
  • Placebo vs SD-809 24 mg/Day · Cochran-Mantel-Haenszel · p = 0.005 (5% level of significance (2-sided)) · Odds ratio (or): 3.96 · 95% CI 1.460 to 10.716SD-809/placebo The odds ratio was the Mantel-Haenszel estimate of the common odds ratio.
  • Placebo vs SD-809 12 mg/Day · Cochran-Mantel-Haenszel · p = 0.829 (5% level of significance (2-sided)) · Odds ratio (or): 1.13 · 95% CI 0.383 to 3.316SD-809/placebo The odds ratio was the Mantel-Haenszel estimate of the common odds ratio.
SecondaryPercent Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model for Repeated Measures (MMRM)

AIMS is an assessment tool used to detect and follow the severity of TD over time. AIMS is composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement. MMRM with treatment group, visit, treatment group-by-visit interaction, and baseline use of DRAs as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.

Time frame:
Day 0 (Baseline), Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · percentage of baseline
Percent Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model for Repeated Measures (MMRM)
percentage of baselinePlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/Day
Percent Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model for Repeated Measures (MMRM)-11.6 ± 4.32-20.0 ± 4.34-31.9 ± 4.73-33.1 ± 4.38
Statistical analysis
  • Placebo vs SD-809 36 mg/Day · mixed model for repeated measures · p = <0.001 (5% level of significance (2-sided). Treatment group, visit, treatment group-by-visit interaction, and baseline use of DRAs as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.) · Mean difference (final values): -21.5 · 95% CI -33.44 to -9.52SD-809 - placebo
  • Placebo vs SD-809 24 mg/Day · mixed model for repeated measures · p = 0.001 (5% level of significance (2-sided). Treatment group, visit, treatment group-by-visit interaction, and baseline use of DRAs as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.) · Mean difference (final values): -20.2 · 95% CI -32.57 to -7.92SD-809 - placebo
  • Placebo vs SD-809 12 mg/Day · mixed model for repeated measures · p = 0.160 (5% level of significance (2-sided). Treatment group, visit, treatment group-by-visit interaction, and baseline use of DRAs as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.) · Mean difference (final values): -8.4 · 95% CI -20.15 to 3.34SD-809 - placebo
SecondaryCumulative Percentage of Responders Based on Change in in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Recorded in Incremental Steps of 10 Percentage Points

AIMS is an assessment tool used to detect and follow the severity of TD over time, composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement. Participants with missing data are classified as non-responders. The responder 95% CI is calculated with the Wilson (score) confidence limits. If any of the expected cell counts are \< 5, exact Clopper Pearson limits are presented. Data report the percentage of participants who responded to the percentage improvement indicated in each row.

Time frame:
Day 0 (Baseline), Week 12
Reported as:
Number · percentage of participants
Cumulative Percentage of Responders Based on Change in in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Recorded in Incremental Steps of 10 Percentage Points
percentage of participantsPlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/Day
10% Improvement50 (37.5 to 62.5)62 (49.0 to 72.9)67 (53.4 to 78.8)71 (57.9 to 81.2)
20% Improvement40 (28.1 to 52.5)47 (34.6 to 59.1)59 (45.2 to 71.8)60 (46.8 to 71.9)
30% Improvement31 (20.6 to 43.8)32 (21.3 to 44.2)49 (35.6 to 62.5)49 (36.4 to 61.9)
40% Improvement16 (8.4 to 26.9)23 (14.4 to 35.4)45 (31.9 to 58.7)40 (28.1 to 53.2)
50% Improvement12 (6.0 to 22.9)13 (6.9 to 24.2)35 (22.9 to 48.7)33 (21.8 to 45.9)
60% Improvement5 (1.8 to 14.1)7 (2.6 to 15.9)20 (11.5 to 33.6)18 (10.2 to 30.3)
70% Improvement2 (0.0 to 9.2)3 (0.4 to 11.5)12 (4.6 to 24.8)16 (7.8 to 28.8)
80% Improvement2 (0.0 to 9.2)2 (0.0 to 8.9)2 (0.1 to 10.9)13 (5.3 to 24.5)
90% Improvement2 (0.0 to 9.2)0 (0.0 to 6.0)0 (0.0 to 7.3)5 (1.1 to 15.1)
SecondaryParticipants With Adverse Events During the Overall Treatment Period

An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator and includes possibly, probably and definitely related categories. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

Time frame:
Day 1 to Week 12
Reported as:
Count of participants · Participants
Participants With Adverse Events During the Overall Treatment Period
ParticipantsPlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/Day
Overall Treatment Period: any AE34363238
Overall Treatment Period: SAE4264
Overall Treatment Period: Severe AE2241
Overall Treatment Period: treatment-related AE19131118
Dose reduction because of AE0013
Dose suspension because of AE2311
Withdrawn from study because of AE2423

Adverse events

Collected over Day 1 to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/72 (0%)4/72 (5.6%)14/72 (19.4%)
SD-809 12 mg/Day0/74 (0%)2/74 (2.7%)9/74 (12.2%)
SD-809 24 mg/Day1/73 (1.4%)6/73 (8.2%)9/73 (12.3%)
SD-809 36 mg/Day1/74 (1.4%)4/74 (5.4%)10/74 (13.5%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/Day
Abdominal painGastrointestinal disorders1/720/740/730/74
Pancreatic massGastrointestinal disorders1/720/740/730/74
Head injuryInjury, poisoning and procedural complications1/720/740/730/74
Neuroendocrine carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/720/740/730/74
Bipolar disorderPsychiatric disorders1/720/740/730/74
Sudden cardiac deathGeneral disorders0/720/741/730/74
AppendicitisInfections and infestations0/720/741/730/74
CellulitisInfections and infestations0/720/741/730/74
PneumoniaInfections and infestations0/720/741/731/74
DepressionPsychiatric disorders0/720/741/730/74
Most frequent other events
Most frequent other events
EventPlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/Day
NauseaGastrointestinal disorders7/721/741/731/74
DiarrhoeaGastrointestinal disorders2/721/743/735/74
HeadacheNervous system disorders4/725/742/735/74
NasopharyngitisInfections and infestations1/724/743/732/74

Baseline characteristics

The Safety Population was a subset of randomized participants and included all patients who were administered study drug (N=293).

Age, Continuous
Age, Continuous(years)PlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/DayTotal
Mean54.6 ± 12.0657.0 ± 9.9555.6 ± 11.3458.3 ± 11.5556.4 ± 11.27
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/DayTotal
Female37424142162
Male35323232131
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/DayTotal
American Indian or Alaska Native11024
Asian00000
Black or African American1215191056
Native Hawaiian or Pacific Islander00000
White59585461232
Other00011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/DayTotal
Hispanic or latino763723
Not hispanic or latino64646965262
Not reported03115
Unknown11013
Weight
Weight(kg)PlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/DayTotal
Mean82.8 ± 18.5180.8 ± 21.0086.8 ± 18.7978.5 ± 17.5682.2 ± 19.16
Height
Height(cm)PlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/DayTotal
Mean168.3 ± 9.25167.7 ± 10.68168.7 ± 9.39167.6 ± 10.55168.1 ± 9.96
Body Mass Index
Body Mass Index(kg/m^2)PlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/DayTotal
Mean29.18 ± 6.12828.69 ± 6.81430.64 ± 7.02127.99 ± 6.17829.12 ± 6.587
Education Level
Education Level(Participants)PlaceboSD-809 12 mg/DaySD-809 24 mg/DaySD-809 36 mg/DayTotal
<= 12 years40444439167
> 12 years32302935126

4 further baseline measures are reported on the registry.

08

Study locations

106 sites
  • Teva Investigational Site 145
    Tuscaloosa, Alabama 35404, United States
  • Teva Investigational Site 107
    Anaheim, California 92804, United States
  • Teva Investigational Site 108
    Anaheim, California 92805, United States
  • Teva Investigational Site 123
    Glendale, California 91206, United States
  • Teva Investigational Site 177
    Imperial, California 92251, United States
  • Teva Investigational Site 160
    Irvine, California 92614, United States
  • Teva Investigational Site 106
    Irvine, California 92697, United States
  • Teva Investigational Site 176
    Loma Linda, California 92354, United States
  • Teva Investigational Site 121
    Los Angeles, California 90033, United States
  • Teva Investigational Site 147
    Los Angeles, California 90095-1769, United States
  • Teva Investigational Site 174
    Norwalk, California 90650, United States
  • Teva Investigational Site 170
    Oceanside, California 92056, United States
  • Teva Investigational Site 102
    Orange, California 92868, United States
  • Teva Investigational Site 104
    San Bernardino, California 92408, United States
  • Teva Investigational Site 110
    San Diego, California 92108, United States
  • Teva Investigational Site 169
    San Rafael, California 94901, United States
  • Teva Investigational Site 129
    Englewood, Colorado 80113, United States
  • Teva Investigational Site 139
    New Haven, Connecticut 06519, United States
  • Teva Investigational Site 156
    Washington D.C., District of Columbia 20007, United States
  • Teva Investigational Site 157
    Boca Raton, Florida 33486, United States
  • Teva Investigational Site 117
    Gainesville, Florida 32607, United States
  • Teva Investigational Site 150
    Lake City, Florida 32025, United States
  • Teva Investigational Site 153
    Miami, Florida 33135, United States
  • Teva Investigational Site 162
    Miami, Florida 33165, United States
  • Teva Investigational Site 112
    Orlando, Florida 32803, United States
  • Teva Investigational Site 144
    Port Charlotte, Florida 33980, United States
  • Teva Investigational Site 155
    Augusta, Georgia 30912, United States
  • Teva Investigational Site 165
    Decatur, Georgia 30033, United States
  • Teva Investigational Site 131
    Chicago, Illinois 60611, United States
  • Teva Investigational Site 113
    Chicago, Illinois 60612, United States
  • Teva Investigational Site 164
    Kansas City, Kansas 66160, United States
  • Teva Investigational Site 154
    Baltimore, Maryland 21287, United States
  • Teva Investigational Site 101
    Glen Burnie, Maryland 21061, United States
  • Teva Investigational Site 135
    Boston, Massachusetts 02215, United States
  • Teva Investigational Site 118
    Creve Coeur, Missouri 63141, United States
  • Teva Investigational Site 142
    Kansas City, Missouri 64108, United States
  • Teva Investigational Site 175
    St Louis, Missouri 63104, United States
  • Teva Investigational Site 161
    St Louis, Missouri 63109, United States
  • Teva Investigational Site 178
    Lincoln, Nebraska 68526-9467, United States
  • Teva Investigational Site 128
    Albuquerque, New Mexico 87106, United States
  • Teva Investigational Site 172
    Commack, New York 11725, United States
  • Teva Investigational Site 148
    New York, New York 10032, United States
  • Teva Investigational Site 138
    Asheville, North Carolina 28805, United States
  • Teva Investigational Site 146
    Raleigh, North Carolina 27610, United States
  • Teva Investigational Site 133
    Charleston, South Carolina 29425, United States
  • Teva Investigational Site 149
    Memphis, Tennessee 38163, United States
  • Teva Investigational Site 151
    Fort Worth, Texas 76104, United States
  • Teva Investigational Site 115
    Salt Lake City, Utah 84105, United States
  • Teva Investigational Site 141
    Salt Lake City, Utah 84108, United States
  • Teva Investigational Site 168
    Burlington, Vermont 05401, United States
  • Teva Investigational Site 171
    Charlottesville, Virginia 22903, United States
  • Teva Investigational Site 167
    Richland, Washington 99352, United States
  • Teva Investigational Site 166
    Waukesha, Wisconsin 53188, United States
  • Teva Investigational Site 559
    Havířov, 736 01, Czechia
  • Teva Investigational Site 556
    Hostivice, 999999, Czechia
  • Teva Investigational Site 558
    Hradec Králové, 503 41, Czechia
  • Teva Investigational Site 535
    Litoměřice, 412 01, Czechia
  • Teva Investigational Site 557
    Pilsen, 312 00, Czechia
  • Teva Investigational Site 533
    Prague, 100 00, Czechia
  • Teva Investigational Site 532
    Prague, 158 00, Czechia
  • Teva Investigational Site 530
    Prague, 16000, Czechia
  • Teva Investigational Site 531
    Prague, 181 02, Czechia
  • Teva Investigational Site 534
    Prague, 190 00, Czechia
  • Teva Investigational Site 502
    Gera, 07551, Germany
  • Teva Investigational Site 503
    Haag in Oberbayern, 83527, Germany
  • Teva Investigational Site 504
    Mainz, 55131, Germany
  • Teva Investigational Site 507
    Prien am Chiemsee, 83209, Germany
  • Teva Investigational Site 544
    Taufkirchen, 84416, Germany
  • Teva Investigational Site 501
    Wolfach, 77709, Germany
  • Teva Investigational Site 540
    Balassagyarmat, 999999, Hungary
  • Teva Investigational Site 538
    Budapest, 1135, Hungary
  • Teva Investigational Site 541
    Budapest, 1148, Hungary
  • Teva Investigational Site 537
    Budapest, 1204, Hungary
  • Teva Investigational Site 542
    Budapest, H-1135, Hungary
  • Teva Investigational Site 539
    Doba, 8482, Hungary
  • Teva Investigational Site 546
    Győr, 9024, Hungary
  • Teva Investigational Site 545
    Kalocsa, 6300, Hungary
  • Teva Investigational Site 547
    Szeged, 6725, Hungary
  • Teva Investigational Site 514
    Bełchatów, 97-400, Poland
  • Teva Investigational Site 554
    Bialystok, 15-756, Poland
  • Teva Investigational Site 510
    Bydgoszcz, 85-015, Poland
  • Teva Investigational Site 519
    Bydgoszcz, 85-080, Poland
  • Teva Investigational Site 536
    Bydgoszcz, 85-156, Poland
  • Teva Investigational Site 523
    Chełmno, 86-200, Poland
  • Teva Investigational Site 517
    Choroszcz, 16-070, Poland
  • Teva Investigational Site 513
    Gdansk, 80-952, Poland
  • Teva Investigational Site 512
    Katowice, 40-097, Poland
  • Teva Investigational Site 552
    Katowice, 40-123, Poland
  • Teva Investigational Site 520
    Krakow, 30-349, Poland
  • Teva Investigational Site 509
    Krakow, 31-505, Poland
  • Teva Investigational Site 508
    Lodz, 90-130, Poland
  • Teva Investigational Site 511
    Lublin, 20-064, Poland
  • Teva Investigational Site 515
    Lublin, 20-090, Poland
  • Teva Investigational Site 524
    Lublin, 20-831, Poland
  • Teva Investigational Site 549
    Olsztyn, 10-443, Poland
  • Teva Investigational Site 521
    Pruszków, 05-802, Poland
  • Teva Investigational Site 518
    Sosnowiec, 41-200, Poland
  • Teva Investigational Site 522
    Torun, 87-100, Poland
  • Teva Investigational Site 550
    Warsaw, 00-465, Poland
  • Teva Investigational Site 555
    Warsaw, 00-669, Poland

Showing the first 100 of 106 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojarvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28. PubMed 28668671 ↗
  • Frank S, Anderson KE, Fernandez HH, Hauser RA, Claassen DO, Stamler D, Factor SA, Jimenez-Shahed J, Barkay H, Wilhelm A, Alexander JK, Chaijale N, Barash S, Savola JM, Gordon MF, Chen M. Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease. Neurol Ther. 2024 Jun;13(3):655-675. doi: 10.1007/s40120-024-00600-1. Epub 2024 Apr 1. PubMed 38557959 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Aug 2016, 21 months.

Results were first posted in Apr 2018, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2014
First posted
Nov 17, 2014
StartActual
Oct 31, 2014
Primary completionActual
Aug 19, 2016
CompletionActual
Aug 19, 2016
Results first posted
Apr 11, 2018
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02291861
Responsible party
Sponsor
First posted
Nov 17, 2014
Start date
Oct 31, 2014
Primary completion
Aug 19, 2016
Completion
Aug 19, 2016
Results posted
Apr 11, 2018
Last update
Jun 23, 2026

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deutetrabenazine

Start the discussion